The combination of<unk>  with either leflunomide or vemurafenib may lead to increased hepatotoxicity. Systemic corticosteroids should be avoided before starting<unk> ; however, systemic corticosteroids may be used to treat an immune-related adverse reaction that arises from<unk>  treatment. Patients taking anticoagulants with<unk>  should be monitored due to an increased risk of gastrointestinal bleeding.
Ipilimumab
Pembrolizumab
Daratumumab
Axitinib
Teprotumumab
Siltuximab
Blinatumomab
Ofatumumab